Chuck Ence bought $299K of Relmada Therapeutics (RLMD)
Executed Nov 5 2025, disclosed Nov 6 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Nov 6 2025), the stock returned +48.8% (delay-adjusted); from the execution session (Nov 5 2025), +56.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Chuck Ence (CAO and COO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 1 priced purchase filing, the average 21-session return was +56.9% from execution and +48.8% from disclosure (delay-adjusted; derived). The largest single filing was $299K of RLMD (136,000 sh × $2.20, as filed), executed Nov 5 2025.
Healthcare · Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→228,961 sh × $0.45
Exec May 16 2025
Filed May 20 2025 · 5:30 PM ET